CD274 and non-small cell lung carcinoma: Anti-PD-1 (nivolumab, pembrolizumab, cemiplimab) and anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab) are on the list of approved agents for different types of cancer, including NSCLC [6,7,8].